8HOH
| Crystal structure of Bcl-2 G101V in complex with sonrotoclax | Descriptor: | Apoptosis regulator Bcl-2, ~{N}-[4-[(4-methyl-4-oxidanyl-cyclohexyl)methylamino]-3-nitro-phenyl]sulfonyl-4-[2-[(2~{S})-2-(2-propan-2-ylphenyl)pyrrolidin-1-yl]-7-azaspiro[3.5]nonan-7-yl]-2-(1~{H}-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide | Authors: | Liu, J, Xu, M, Feng, Y, Hong, Y, Liu, Y. | Deposit date: | 2022-12-10 | Release date: | 2024-01-17 | Last modified: | 2024-05-15 | Method: | X-RAY DIFFRACTION (1.9 Å) | Cite: | Sonrotoclax overcomes BCL2 G101V mutation-induced venetoclax resistance in preclinical models of hematologic malignancy. Blood, 143, 2024
|
|
8HOG
| Crystal structure of Bcl-2 in complex with sonrotoclax | Descriptor: | Apoptosis regulator Bcl-2, ~{N}-[4-[(4-methyl-4-oxidanyl-cyclohexyl)methylamino]-3-nitro-phenyl]sulfonyl-4-[2-[(2~{S})-2-(2-propan-2-ylphenyl)pyrrolidin-1-yl]-7-azaspiro[3.5]nonan-7-yl]-2-(1~{H}-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide | Authors: | Liu, J, Xu, M, Feng, Y, Hong, Y, Liu, Y. | Deposit date: | 2022-12-10 | Release date: | 2024-01-17 | Last modified: | 2024-05-15 | Method: | X-RAY DIFFRACTION (1.8 Å) | Cite: | Sonrotoclax overcomes BCL2 G101V mutation-induced venetoclax resistance in preclinical models of hematologic malignancy. Blood, 143, 2024
|
|
8HOI
| Crystal structure of Bcl-2 D103Y in complex with sonrotoclax | Descriptor: | Apoptosis regulator Bcl-2, FORMIC ACID, ~{N}-[4-[(4-methyl-4-oxidanyl-cyclohexyl)methylamino]-3-nitro-phenyl]sulfonyl-4-[2-[(2~{S})-2-(2-propan-2-ylphenyl)pyrrolidin-1-yl]-7-azaspiro[3.5]nonan-7-yl]-2-(1~{H}-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide | Authors: | Liu, J, Xu, M, Feng, Y, Hong, Y, Liu, Y. | Deposit date: | 2022-12-10 | Release date: | 2024-01-17 | Last modified: | 2024-05-15 | Method: | X-RAY DIFFRACTION (2.25 Å) | Cite: | Sonrotoclax overcomes BCL2 G101V mutation-induced venetoclax resistance in preclinical models of hematologic malignancy. Blood, 143, 2024
|
|
6LHD
| Crystal structure of p53/BCL-xL fusion complex | Descriptor: | ZINC ION, fusion protein of Bcl-2-like protein 1 and Isoform 6 of Cellular tumor antigen p53 | Authors: | Wei, H, Chen, Y. | Deposit date: | 2019-12-07 | Release date: | 2021-03-31 | Last modified: | 2023-11-22 | Method: | X-RAY DIFFRACTION (2.499 Å) | Cite: | Structural insight into the molecular mechanism of p53-mediated mitochondrial apoptosis. Nat Commun, 12, 2021
|
|
1TY4
| Crystal structure of a CED-9/EGL-1 complex | Descriptor: | Apoptosis regulator ced-9, EGg Laying defective EGL-1, programmed cell death activator | Authors: | Yan, N, Gu, L, Kokel, D, Xue, D, Shi, Y. | Deposit date: | 2004-07-07 | Release date: | 2004-09-28 | Last modified: | 2011-07-13 | Method: | X-RAY DIFFRACTION (2.2 Å) | Cite: | Structural, Biochemical, and Functional Analyses of CED-9 Recognition by the Proapoptotic Proteins EGL-1 and CED-4 Mol.Cell, 15, 2004
|
|
1GJH
| HUMAN BCL-2, ISOFORM 2 | Descriptor: | PROTEIN (APOPTOSIS REGULATOR BCL-2 WITH PUTATIVE FLEXIBLE LOOP REPLACED WITH A PORTION OF APOPTOSIS REGULATOR BCL-X PROTEIN) | Authors: | Petros, A.M, Medek, A, Nettesheim, D.G, Kim, D.H, Yoon, H.S, Swift, K, Matayoshi, E.D, Oltersdorf, T, Fesik, S.W. | Deposit date: | 2001-05-31 | Release date: | 2001-06-13 | Last modified: | 2023-12-27 | Method: | SOLUTION NMR | Cite: | Solution structure of the antiapoptotic protein bcl-2. Proc.Natl.Acad.Sci.USA, 98, 2001
|
|
1G5J
| COMPLEX OF BCL-XL WITH PEPTIDE FROM BAD | Descriptor: | APOPTOSIS REGULATOR BCL-X, BAD PROTEIN | Authors: | Petros, A.M, Nettesheim, D.G, Wang, Y, Olejniczak, E.T, Meadows, R.P, Mack, J, Swift, K, Matayoshi, E.D, Zhang, H, Thompson, C.B, Fesik, S.W. | Deposit date: | 2000-11-01 | Release date: | 2001-02-07 | Last modified: | 2024-05-22 | Method: | SOLUTION NMR | Cite: | Rationale for Bcl-xL/Bad peptide complex formation from structure, mutagenesis, and biophysical studies. Protein Sci., 9, 2000
|
|
1G5M
| HUMAN BCL-2, ISOFORM 1 | Descriptor: | PROTEIN (APOPTOSIS REGULATOR BCL-2 WITH PUTATIVE FLEXIBLE LOOP REPLACED WITH A PORTION OF APOPTOSIS REGULATOR BCL-X PROTEIN) | Authors: | Petros, A.M, Medek, A, Nettesheim, D.G, Kim, D.H, Yoon, H.S, Swift, K, Matayoshi, E.D, Oltersdorf, T, Fesik, S.W. | Deposit date: | 2000-11-01 | Release date: | 2001-03-21 | Last modified: | 2024-05-22 | Method: | SOLUTION NMR | Cite: | Solution structure of the antiapoptotic protein bcl-2. Proc.Natl.Acad.Sci.USA, 98, 2001
|
|
1R2H
| Human Bcl-XL containing an Ala to Leu mutation at position 142 | Descriptor: | Apoptosis regulator Bcl-X | Authors: | O'Neill, J.W, Manion, M.K, Giedt, C.D, Kim, K.M, Zhang, K.Y, Hockenbery, D.M. | Deposit date: | 2003-09-26 | Release date: | 2004-02-03 | Last modified: | 2023-08-23 | Method: | X-RAY DIFFRACTION (2.2 Å) | Cite: | Bcl-XL mutations suppress cellular sensitivity to antimycin A. J.Biol.Chem., 279, 2004
|
|
1R2D
| Structure of Human Bcl-XL at 1.95 Angstroms | Descriptor: | Apoptosis regulator Bcl-X | Authors: | O'Neill, J.W, Manion, M.K, Giedt, C.D, Kim, K.M, Zhang, K.Y, Hockenbery, D.M. | Deposit date: | 2003-09-26 | Release date: | 2004-02-03 | Last modified: | 2023-08-23 | Method: | X-RAY DIFFRACTION (1.95 Å) | Cite: | Bcl-XL mutations suppress cellular sensitivity to antimycin A. J.Biol.Chem., 279, 2004
|
|
5C3G
| Crystal structure of Bcl-xl bound to BIM-MM | Descriptor: | Bcl-2-like protein 1,Bcl-2-like protein 1, Bcl-2-like protein 11 | Authors: | Miles, J.A, Yeo, D.J, Rowell, P, Rodriguez-Marin, S, Pask, C.M, Warriner, S.L, Edwards, T.A, Wilson, A.J. | Deposit date: | 2015-06-17 | Release date: | 2016-04-20 | Last modified: | 2024-01-10 | Method: | X-RAY DIFFRACTION (2.45 Å) | Cite: | Hydrocarbon constrained peptides - understanding preorganisation and binding affinity. Chem Sci, 7, 2016
|
|
6IJQ
| Solution structure of BCL-XL bound to P73-TAD peptide | Descriptor: | Bcl-2-like protein 1,Bcl-2-like protein 1, Tumor protein p73 | Authors: | Yoon, M.-K, Ha, J.-H, Lee, M.-S, Chi, S.-W. | Deposit date: | 2018-10-11 | Release date: | 2018-11-21 | Last modified: | 2024-05-29 | Method: | SOLUTION NMR | Cite: | Cytoplasmic pro-apoptotic function of the tumor suppressor p73 is mediated through a modified mode of recognition of the anti-apoptotic regulator Bcl-XL. J. Biol. Chem., 293, 2018
|
|
3FDL
| Bim BH3 peptide in complex with Bcl-xL | Descriptor: | Apoptosis regulator Bcl-X, Bcl-2-like protein 11 | Authors: | Fairlie, W.D, Lee, E.F, Smith, B.J, Czabotar, P.E, Colman, P.M. | Deposit date: | 2008-11-26 | Release date: | 2009-03-10 | Last modified: | 2023-11-01 | Method: | X-RAY DIFFRACTION (1.78 Å) | Cite: | High-Resolution Structural Characterization of a Helical alpha/beta-Peptide Foldamer Bound to the Anti-Apoptotic Protein Bcl-x(L) Angew.Chem.Int.Ed.Engl., 48, 2009
|
|
3CVA
| Human Bcl-xL containing a Trp to Ala mutation at position 137 | Descriptor: | Apoptosis regulator Bcl-X | Authors: | Feng, Y, Zhang, L, Hu, T, Shen, X, Chen, K, Jiang, H, Liu, D. | Deposit date: | 2008-04-18 | Release date: | 2009-03-24 | Last modified: | 2023-11-01 | Method: | X-RAY DIFFRACTION (2.7 Å) | Cite: | A conserved hydrophobic core at Bcl-x(L) mediates its structural stability and binding affinity with BH3-domain peptide of pro-apoptotic protein Arch.Biochem.Biophys., 484, 2009
|
|
3FDM
| alpha/beta foldamer in complex with Bcl-xL | Descriptor: | 1,2-ETHANEDIOL, Apoptosis regulator Bcl-X, alpha/beta-peptide foldamer | Authors: | Fairlie, W.D, Lee, E.F, Smith, B.J, Czabotar, P.E, Colman, P.M, Sadowsky, J.D, Peterson-Kaufman, K.J, Gellman, S.H. | Deposit date: | 2008-11-26 | Release date: | 2009-03-10 | Last modified: | 2023-11-15 | Method: | X-RAY DIFFRACTION (2.26 Å) | Cite: | High-Resolution Structural Characterization of a Helical alpha/beta-Peptide Foldamer Bound to the Anti-Apoptotic Protein Bcl-x(L) Angew.Chem.Int.Ed.Engl., 48, 2009
|
|
7JGV
| CRYSTAL STRUCTURE OF BCL-XL IN COMPLEX WITH COMPOUND 1620116, CRYSTAL FORM 2 | Descriptor: | 6-[(8E)-8-{2-[4-(benzylcarbamoyl)-1,3-thiazol-2-yl]hydrazinylidene}-5,6,7,8-tetrahydronaphthalen-2-yl]-3-(2-phenylethoxy)pyridine-2-carboxylic acid, Bcl-2-like protein 1 | Authors: | Lee, M, Fairlie, W.D, Smith, B.J, Lee, E.F. | Deposit date: | 2020-07-19 | Release date: | 2021-02-24 | Last modified: | 2023-10-18 | Method: | X-RAY DIFFRACTION (2.05 Å) | Cite: | Optimization of Benzothiazole and Thiazole Hydrazones as Inhibitors of Schistosome BCL-2. Acs Infect Dis., 7, 2021
|
|
7JGW
| Crystal structure of BCL-XL in complex with COMPOUND 1620116, CRYSTAL FORM 1 | Descriptor: | 6-[(8E)-8-{2-[4-(benzylcarbamoyl)-1,3-thiazol-2-yl]hydrazinylidene}-5,6,7,8-tetrahydronaphthalen-2-yl]-3-(2-phenylethoxy)pyridine-2-carboxylic acid, Bcl-2-like protein 1 | Authors: | Lee, M, Fairlie, W.D, Smith, B.J, Lee, E.F. | Deposit date: | 2020-07-19 | Release date: | 2021-02-24 | Last modified: | 2023-10-18 | Method: | X-RAY DIFFRACTION (1.3 Å) | Cite: | Optimization of Benzothiazole and Thiazole Hydrazones as Inhibitors of Schistosome BCL-2. Acs Infect Dis., 7, 2021
|
|
3D7V
| Crystal structure of Mcl-1 in complex with an Mcl-1 selective BH3 ligand | Descriptor: | Bcl-2-like protein 11, Induced myeloid leukemia cell differentiation protein Mcl-1, ZINC ION | Authors: | Lee, E.F, Czabotar, P.E, Colman, P.M, Fairlie, W.D. | Deposit date: | 2008-05-22 | Release date: | 2008-06-24 | Last modified: | 2023-11-01 | Method: | X-RAY DIFFRACTION (2.03 Å) | Cite: | A novel BH3 ligand that selectively targets Mcl-1 reveals that apoptosis can proceed without Mcl-1 degradation. J.Cell Biol., 180, 2008
|
|
6IWB
| Crystal structure of a computationally designed protein (LD3) in complex with BCL-2 | Descriptor: | Apolipoprotein E, Apoptosis regulator Bcl-2,Apoptosis regulator Bcl-2, SULFATE ION | Authors: | Kim, S, Kwak, M.J, Oh, B.-H, Correia, B.E, Gainza, P. | Deposit date: | 2018-12-05 | Release date: | 2019-12-11 | Last modified: | 2024-03-27 | Method: | X-RAY DIFFRACTION (2.5 Å) | Cite: | A computationally designed chimeric antigen receptor provides a small-molecule safety switch for T-cell therapy. Nat.Biotechnol., 38, 2020
|
|
5FCG
| |
8IQK
| Structural basis of the specificity and interaction mechanism of Bmf binding to pro-survival proteins | Descriptor: | Bcl-2-like protein 1, Bcl-2-modifying factor | Authors: | Wang, H, Guo, M, Wei, H, Chen, Y. | Deposit date: | 2023-03-16 | Release date: | 2023-08-23 | Method: | X-RAY DIFFRACTION (2.879 Å) | Cite: | Structural basis of the specificity and interaction mechanism of Bmf binding to pro-survival Bcl-2 family proteins. Comput Struct Biotechnol J, 21, 2023
|
|
5FMJ
| Bcl-xL with mouse Bak BH3 Q75L complex | Descriptor: | 1,2-ETHANEDIOL, BAK1 PROTEIN, BCL-2-LIKE PROTEIN 1 | Authors: | Fairlie, W.D, Lee, E.F, Smith, B.J. | Deposit date: | 2015-11-06 | Release date: | 2016-06-01 | Last modified: | 2024-01-10 | Method: | X-RAY DIFFRACTION (2.43 Å) | Cite: | Physiological Restraint of Bak by Bcl-Xl is Essential for Cell Survival. Genes Dev., 30, 2016
|
|
5FMK
| Bcl-xL with Bak BH3 complex | Descriptor: | BCL-2 HOMOLOGOUS ANTAGONIST/KILLER, BCL-XL, GLYCEROL | Authors: | Fairlie, W.D, Lee, E.F, Smith, B.J, Czabotar, P.E, Colman, P.M. | Deposit date: | 2015-11-06 | Release date: | 2016-06-01 | Last modified: | 2024-01-10 | Method: | X-RAY DIFFRACTION (1.731 Å) | Cite: | Physiological Restraint of Bak by Bcl-Xl is Essential for Cell Survival. Genes Dev., 30, 2016
|
|
4K5A
| Co-crystallization with conformation-specific designed ankyrin repeat proteins explains the conformational flexibility of BCL-W | Descriptor: | Bcl-2-like protein 2, Designed Ankyrin Repeat Protein 013_D12 | Authors: | Schilling, J, Schoeppe, J, Sauer, E, Plueckthun, A. | Deposit date: | 2013-04-14 | Release date: | 2014-04-16 | Last modified: | 2024-03-20 | Method: | X-RAY DIFFRACTION (1.5 Å) | Cite: | Co-Crystallization with Conformation-Specific Designed Ankyrin Repeat Proteins Explains the Conformational Flexibility of BCL-W J.Mol.Biol., 426, 2014
|
|
5JSN
| Bcl2-inhibitor complex | Descriptor: | Apoptosis regulator Bcl-2, Bcl2 inhibitor | Authors: | Shen, B.W, Stoddard, B.L. | Deposit date: | 2016-05-09 | Release date: | 2016-11-16 | Last modified: | 2024-03-06 | Method: | X-RAY DIFFRACTION (2.1 Å) | Cite: | Computationally designed high specificity inhibitors delineate the roles of BCL2 family proteins in cancer. Elife, 5, 2016
|
|